Related Experiment Video
Updated: Jun 2, 2025
Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens
Published on: April 5, 2019
Development of a broad-spectrum epitope-based vaccine against Streptococcus pneumoniae
Md Nahian1, Muhammad Shahab2, Md Rasel Khan1
1Department of Microbiology, Jagannath University, Dhaka, Bangladesh.
Insights
A novel peptide vaccine targeting Streptococcus pneumoniae (SPN) shows promise for a cost-effective, broad-spectrum solution. Computational analysis indicates a stable, antigenic, and immunogenic vaccine candidate against pneumonia and meningitis.
Area of Science:
- Microbiology
- Immunology
- Vaccine Development
Background:
- Streptococcus pneumoniae (SPN) causes severe pneumonia and meningitis, disproportionately affecting vulnerable populations.
- Current vaccines have limitations including serotype specificity and high production costs, compounded by rising antibiotic resistance.
- There is a critical need for a new, cost-effective, broad-spectrum SPN vaccine.
Purpose of the Study:
- To design and computationally validate a novel peptide vaccine construct against Streptococcus pneumoniae.
- To predict and link B-cell, CTL, and HTL epitopes with adjuvants and a PADRE sequence for enhanced immunogenicity.
- To assess the vaccine candidate's structural stability, binding interactions, and potential for effective cloning and immune response.
Main Methods:
- Epitope prediction and linkage using bioinformatics tools, incorporating linkers, adjuvants, and PADRE sequence.
- In silico analysis of vaccine construct properties including antigenicity, toxicity, allergenicity, and solubility.
- 3D structure modeling, molecular docking (ClusPro, iMOD, Amber v.22), cloning efficiency assessment (GenScript, SnapGene), and immunogenicity prediction (C-IMMSIM).
Main Results:
- The designed peptide vaccine construct demonstrated favorable antigenic, non-toxic, non-allergenic, and soluble properties.
- Computational validation confirmed stable binding interactions with toll-like receptor 4 in humans and animals.
- In silico cloning and immunogenicity prediction suggested high efficiency and enhanced immune responses.
Conclusions:
- A promising peptide vaccine candidate against Streptococcus pneumoniae has been computationally designed and validated.
- The construct exhibits desirable characteristics for stability, binding, and potential immunogenicity.
- Further experimental validation is crucial to confirm the efficacy of this potential rapid and cost-effective vaccine solution.
Abstract:
Streptococcus pneumoniae (SPN) is a significant pathogen causing pneumonia and meningitis, particularly in vulnerable populations like children and the elderly. Available pneumonia vaccines have limitations since they only cover particular serotypes and have high production costs. The emergence of antibiotic-resistant SPN strains further underscores the need for a new, cost-effective, broad-spectrum vaccine. Two potential vaccine candidates, CbpA and PspA, were identified, and their B-cell, CTL, and HTL epitopes were predicted and connected with suitable linkers, adjivant and PADRE sequence. The vaccine construct was found to be antigenic, non-toxic, non-allergenic, and soluble. The three-dimensional structure of the vaccine candidate was built and validated. Docking analysis of the vaccine candidate by ClusPro demonstrated robust and stable binding interactions between the MEV and toll-like receptor 4 in both humans and animals. The iMOD server and Amber v.22 tool has verified the stability of the docking complexes. GenScript server confirmed the high efficiency of cloning for the construct and in-silico cloning into the pET28a (+) vector using SnapGene, demonstrating successful translation of the epitope region. Immunological responses were shown to be enhanced by the C-IMMSIM server. This study introduced a strong peptide vaccine candidate that has the potential to contribute to the development of a rapid and cost-effective solution for combating SPN. However, experimental verification is necessary to evaluate the vaccine's effectiveness.
